Dose Sparing and Safety-Enhancing Effects of an IGF-I-Based Dosing Regimen in Short Children Treated with Growth Hormone in a 2-Year Randomized Controlled Trial: Therapeutic and Pharmacoeconomic Considerations

Trial Profile

Dose Sparing and Safety-Enhancing Effects of an IGF-I-Based Dosing Regimen in Short Children Treated with Growth Hormone in a 2-Year Randomized Controlled Trial: Therapeutic and Pharmacoeconomic Considerations

Completed
Phase of Trial: Phase IV

Latest Information Update: 24 Jul 2012

At a glance

  • Drugs Somatropin (Primary)
  • Indications Short stature
  • Focus Therapeutic Use
  • Most Recent Events

    • 24 Jul 2012 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top